What is safe therapy of type 2 diabetes mellitus? A current review in four parts. Part II: Epidemiological data from Germany;Was ist gesichert in der therapie des typ-2-diabetikers? Ein aktueller überblick in vier teilen: Teil II: Epidemiologische daten aus Deutschland

Zeitschrift fur Allgemeinmedizin

Volumn 77, Issue 10, 2001, Pages 455-459

  Chantelau, E ^a   Abholz, H H ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT;

AMPUTATION; CARDIOVASCULAR DISEASE; DIALYSIS; DRUG SAFETY; GERMANY; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW;

EID: 0035173997     PISSN: 09376801     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Hospital use among diabetic patients and the general population
2. 5-Year overall survival rates of uremic type 1 and type 2 diabetic patients in comparison with age-matched non-diabetic patients with end-stage renal disease from a single dialysis center from 1991-1997
3. Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes. The WHO multinational study of vascular disease in diabetes
4. Incidence of blindness due to diabetic eye disease in Fife 1990-9
5. Serious questions over the efficacy of intensive glycemic control on type-2 diabetes outcomes: A metaanalysis of major randomized trials
6. Mean life expectancy in diabetes is greater than in non-diabetes
7. Microalbuminuria in patients with type 2 diabetes mellitus from general practice: Course and predictive value
8. Well-being and symptoms in relation to insulin therapy in type 2 diabetes
9. Epidemiologie, prise en charge et cout du diabete de type 2 en France en 1998
10. Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes
11. Nontraumatic lower extremity amputations in the MEDICARE end-stage renal disease population
12. Longitudinal study on glycaemic control and quality of life in patients with type-2 diabetes mellitus referred for intensified control
13. Relationship between glycohemoglobin (GHB) and mean blood glucose (MBG) in the Diabetes Control and Complications Trial (DCCT)
14. Economic and clinical impact of alternative disease management startegies for secondary prevention in type-2 diabetes in the Swiss setting
15. Erblindungsursachen in Hessen 1996
16. Diabetes-Vereinbarungen-Zwischenergebnisse der wissenschaftlichen Begleitforschung liegert vor
17. Relationship between blood glucose level and mortality in type-2 diabetes mellitus: A systematic review
18. Diabetesvereinbarung KV Südwürttemberg: Erfahrung nach dem ersten Jahr der elektronischen dokumentation
19. Harnuntersuchungen zur differenzierten diagnostik einer proteinurie
20. Blindness due to diabetes: Population-based age- and sex-specific incidence rates
21. Amputationshäufigkeit der unteren extremitäten bei patienten mit diabetes mellitus in zwei regionen in Thüringen
22. The prevalence of multiple diabetes-related complications
23. Ergebnisse der diabetesvereinbarung in Thüringen
24. Long term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: The Verona Diabetes Study
25. Prognosis of diabetes mellitus in a geographically defined population
26. Mortality and survival in type-2 (non-insulin-dependent) diabetes mellitus
27. Well-being and treatment satisfaction in older people with diabetes
28. Prävalenz diabetesbedingter erblindungen. Eine populationsstudie an 70203 diabetikern
29. Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age
30. Neue Bundesländer - Gewisse Umstände
31. Structure and strategy of diabetes health care in the German Democratic Republic
32. Amputationen und mortalität bei älteren, insulinpflichtigen patienten mit typ-2-diabetes
33. Failure of reducing lower extremity amputations in diabetic patients: Results of two subsequent population based surveys 1990 and 1995 in Germany
34. Incidence rates of diabetes related events in type 2 diabetic subjects by updated mean haemoglobin alc
35. Evaluating patient preferences for states of health and quality of life in persons with type 2 diabetes
36. Glycaemia and insulinaemia in elderly European subjects (70-75 years)
37. lgA-nepropathie
38. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial
39. Well-being and symptoms in elderly type 2 diabetes patients with poor metabolic control: Effect of insulin treatment
40. Incidence of blindness in relation to diabetes- a population based study
41. Incidence of lower limb amputations and diabetes
42. Incidence of blindness in southern Germany between 1990 and 1998
43. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UKPDS 23
44. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type-2 diabetes mellitus. UKPDS 49
45. UK Prospective Diabetes Study (UKPDS) VIII: Study design, progress and performance
46. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes mellitus (UKPDS 33)
47. Effect of intensive blood glucose control with metformin in overweight patients with type-2 diabetes (UKPDS 34)
48. Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes: UKPDS 38
49. Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type-2 diabetes: UKPDS 39
50. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose of blood pressure control: UKPDS 37
51. Diabetic peripheral neuropathy: Effects of age, duration of diabetes, glycemic control and vascular factors
52. No improvement in quality of life after starting insulin treatment in NIDDM patients
53. Randomized study of two different target levels of glycemic control within acceptable range in type-2 diabetes
54. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes
55. Age-related macular degeneration in newly diagnosed type 2 diabetic patients and control subjects
56. The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus
57. Quartalsbericht zu den diabetes-verträgen der KV nordrhein im 2